Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02614404
Other study ID # HuLow-201605
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 2015
Est. completion date February 2, 2017

Study information

Verified date February 2021
Source HuLow
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.


Description:

An exploratory study to examine the efficacy and safety of imatinib mesylate in combination with dihydroartemisinin plus piperaquine on suppression of parasitemia in patients with uncomplicated Plasmodium falciparum malaria. In vitro studies of P. falciparum parasitized erythrocytes demonstrate that inhibitors of the protein tyrosine kinase SYK prevent malaria parasite egress from infected red blood cells and thereby terminate the parasite's life cycle. Although no potent syk kinase inhibitors were approved for human use at the time of initiation of this study, a bcr-abl tyrosine kinase inhibitor (imatinib mesylate (GleevecĀ®)) that also exhibits off-target inhibition of syk tyrosine kinase, has been FDA-approved for treatment of a number of human malignancies including chronic myelogenous leukemia and GIST. Because imatinib can be taken daily for many years without significant toxicity, it can be used to obtain a preliminary indication of whether inhibition of erythrocyte syk kinase can suppress parasitemia in patients with P. falciparum malaria. In a phase 1 clinical trial on the same patient population, anti-malaria activity was observed with imatinib, with little or no accompanying toxicity. Because dihydroartemisinin plus piperaquine constitute the currently used standard-of-care therapy for malaria in Southeast Asia, the above trial will test the safety and efficacy of the combination of imatinib plus dihydroartemisinin and piperaquine in treatment of uncomplicated malaria. In this pilot study, the rate of decrease in peripheral blood parasitemia in 30 adult male patients with uncomplicated malaria will be compared to the same rate of decrease in parasitemia in 30 adult male patients treated solely with dihydroartemisinin plus piperaquine.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date February 2, 2017
Est. primary completion date December 2, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Gender: only adults are selected for the trial; note that female subjects cannot be women of child-bearing age. - Age: 18-50 years. - Target disease: Uncomplicated Plasmodium falciparum malaria Exclusion Criteria: - symptoms and signs of complicated malaria - including continuous high fever of over 390C, psychiatric disorders, confusion, other neurological symptoms, symptoms and signs of functional impairment of the organs such as lungs, kidneys or cardiovascular system; - symptoms and signs of liver damage or kidney damage - symptoms and signs of another complicating infection such as pneumonia, dengue fever, and other bacterial infection. - P. falciparum > 25.000 / mm3 - WBC <4000 and >10.000 /mm3 - RBC < 3.5x106/mm3 - Platelets < 40.000 /mm3 - Hemoglobin < 10 g/dL - ALT more than 200% of the upper limit (56 units/L) - AST more than 200% of the upper limit (40 units/L) - Blood creatine more than 75% of the upper limit (men: 1.2 mg/dL, women 1 mgdL) - Serum total protein < 6 g/L - Glycemia < 50 mg/dL> 200 mg/dL - Standard urine test Serious alterations - Concomitant treatments Antimalarial Drugs Anticoagulant therapy

Study Design


Intervention

Drug:
Imatinib combination therapy
Imatinib plus dihydroartemisinin plus piperaquine
Dihydroartemisinin-piperaquine
Standard of care

Locations

Country Name City State
Vietnam A Tuc Huong Hoa Quang Tri

Sponsors (5)

Lead Sponsor Collaborator
HuLow Hue University, Purdue University, Università degli Studi di Sassari, University of Turin, Italy

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Parasite Clearance Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis From baseline to the time point when the blood parasite count is zero (up to a maximum of 5 days)
Primary 28-day Cure Rate 28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment and no evidence of recurrent infection with the same parasite genotype after reduction of the asexual parasitemia. Follow up after treatment will only be performed in the case of complete clearance of parasites at D5 due to Imatinib treatment. Day 28
Secondary Frequency of adverse events Adverse events (AEs) are defined as events possibly related to the study drug as judged by physician that occur within 1 week of beginning treatment with imatinib.
Incidence, severity, drug-relatedness, seriousness of adverse events
Laboratory values (biochemistry and haematology)
Vital signs
Within 1 week of beginning treatment with imatinib
See also
  Status Clinical Trial Phase
Completed NCT04577066 - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. Phase 1/Phase 2
Completed NCT01883609 - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S Phase 1/Phase 2
Completed NCT00593398 - Malarial Immunity in Pregnant Cameroonian Women
Completed NCT01659281 - Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand N/A
Completed NCT00074841 - Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India Phase 2/Phase 3
Recruiting NCT04416945 - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic N/A
Completed NCT00314899 - Fetal Immunity to Falciparum Malaria
Completed NCT02867059 - SJ733 Induced Blood Stage Malaria Challenge Study Phase 1
Completed NCT00701961 - Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy Phase 2/Phase 3
Completed NCT00707200 - The Cytoadherence in Pediatric Malaria (CPM) Study N/A
Completed NCT00338520 - Hyperphenylalaninemia in Cerebral Malaria N/A
Completed NCT00393757 - Malaria Transmission and Immunity in Highland Kenya
Completed NCT03783299 - Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic Phase 4
Completed NCT00358332 - Phase I Pediatric FMP2.1/AS02A Trial in Mali Phase 1
Completed NCT00730782 - Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers Phase 1
Completed NCT00349713 - FMP2.1 Trial in Bandiagara, Mali Phase 1
Recruiting NCT05052502 - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand N/A
Completed NCT04093765 - Mass Screening and Treatment for Reduction of Falciparum Malaria N/A
Completed NCT03764527 - Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar Phase 4
Completed NCT03773536 - Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar Phase 4